

**Organisation Strategy for  
 Denmark's engagement with  
 International Partnership for Microbicides (IPM)  
 2014-2018**

**The work of IPM**

IPM is leading partner in the global HIV/AIDS response with a special focus on women. It is a non-profit product development partnership (PDP) with a mission to provide safe, affordable and effective microbicide-based HIV prevention technologies which can be controlled by women. Microbicides are medicines being developed based on antiretroviral drugs already used successfully to *treat* AIDS, but now used to offer *protection* against HIV. PDPs are non-profit product development partnerships which generate resources and forge partnerships across public, private and philanthropic sectors to accelerate development of new health technologies.

IPM	
Established	2002
HQ	Silver Spring, MD, USA
Field offices	7 research centre partners in 2 countries
Human resources	71
CEO	Dr Zeda Rosenberg
Financial resources	32 mill. USD (2013)
Denmark's contribution	5 mill. DKK annually

**Denmark supports IPM because**

- IPM offers novel solutions to address the sexual and reproductive health and rights of women and girls.
- IPM's work can improve maternal and child health, reduce gender based violence and reduce HIV infection.

**Key challenges for IPM**

- Attracting sufficient funding as research requires long term funding and outcomes are not certain.
- Ability to meet the expected demand for the products upon scientific approval.


**Denmark will expect IPM to**

- Focus on technologies relevant and accessible to the most vulnerable and marginalised population groups.
- Ensure availability as quickly as possible and at the lowest possible cost.

**Denmark will follow-up by**

- Monitoring Danish priority areas based on IPM's own framework
- Participating in annual donor consultations.

**Donors (2014)**



BMGF: Bill & Melinda Gates Foundation